Mostrar el registro sencillo del ítem

dc.contributor.authorPun-García, Andrés
dc.contributor.authorClemente-Moragón, Agustín
dc.contributor.authorVillena-Gutierrez, Rocio 
dc.contributor.authorGómez, Monica
dc.contributor.authorSanz-Rosa, David 
dc.contributor.authorDíaz-Guerra, Anabel
dc.contributor.authorPrados, Belén
dc.contributor.authorMedina, Juan Pablo
dc.contributor.authorMontó, Fermí
dc.contributor.authorIvorra, Maria Dolores
dc.contributor.authorMárquez-López, Cristina
dc.contributor.authorCannavo, Alessandro
dc.contributor.authorBernal, Juan A
dc.contributor.authorKoch, Walter J
dc.contributor.authorFuster, Valentin 
dc.contributor.authorde la Pompa, Jose Luis 
dc.contributor.authorOliver, Eduardo 
dc.contributor.authorIbáñez, Borja 
dc.date.accessioned2022-12-15T12:32:25Z
dc.date.available2022-12-15T12:32:25Z
dc.date.issued2022-11-29
dc.identifier.citationBasic Res Cardiol. 2022 Nov 29;117(1):62es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/15275
dc.description.abstractAortic stenosis (AS) is associated with left ventricular (LV) hypertrophy and heart failure (HF). There is a lack of therapies able to prevent/revert AS-induced HF. Beta3 adrenergic receptor (β3AR) signaling is beneficial in several forms of HF. Here, we studied the potential beneficial effect of β3AR overexpression on AS-induced HF. Selective β3AR stimulation had a positive inotropic effect. Transgenic mice constitutively overexpressing human β3AR in the heart (c-hβ3tg) were protected from the development of HF in response to induced AS, and against cardiomyocyte mitochondrial dysfunction (fragmented mitochondria with remodeled cristae and metabolic reprogramming featuring altered substrate use). Similar beneficial effects were observed in wild-type mice inoculated with adeno-associated virus (AAV9) inducing cardiac-specific overexpression of human β3AR before AS induction. Moreover, AAV9-hβ3AR injection into wild-type mice at late disease stages, when cardiac hypertrophy and metabolic reprogramming are already advanced, reversed the HF phenotype and restored balanced mitochondrial dynamics, demonstrating the potential of gene-therapy-mediated β3AR overexpression in AS. Mice with cardiac specific ablation of Yme1l (cYKO), characterized by fragmented mitochondria, showed an increased mortality upon AS challenge. AAV9-hβ3AR injection in these mice before AS induction reverted the fragmented mitochondria phenotype and rescued them from death. In conclusion, our results step out that β3AR overexpression might have translational potential as a therapeutic strategy in AS-induced HF.es_ES
dc.description.sponsorshipSpanish Ministry of Science and Innovation (MICINN) RETOS2019-107332RB-I00, European Commission (ERC-CoG grant N° 819775), ERA-CVD Joint Translational Call 2016 (funded through the Instituto de Salud Carlos III (ISCIII) and the European Regional Development Fund (ERDF), # AC16/00021), and BBVA foundation grant (# BIO CAR 0265) to B.I. PID2019-104776RB-I00, CB16/11/00399 (CIBER CV), and RD16/0011/0021 (TERCEL) from MCIN/AEI/ https://doi.org/10.13039/501100011033and a grant from the Fundación BBVA (Ref.: BIO14_298) to J.L.d.l.P. E.O. is recipient of funds from Programa de Atracción de Talento (2017-T1/BMD-5185) of Comunidad de Madrid and from a Ramón y Cajal grant (RYC2020- 028884-I) funded by MCIN/AEI/ https://doi.org/10.13039/50110 0011033 and by “ESF Investing in your future. A.P. is benefciary of a FPI fellowship by the MCI (BES-2012–061091), R.V-G. of a Spanish National doctorate fellowship funded by ISCIII (Contratos PFIS FI17/00045) and A.C-M. is benefciary of a FPU fellowship from the MCI (FPU2017/01932). This study was partially supported by the Comunidad de Madrid (RENIM-CM, S2017/BMD-3867 & P2022/ BMD-7403) and cofunded with European structural and investment funds. The CNIC is supported by the ISCIII, the MICINN and the Pro CNIC Foundation, and is a Center of Excellence Severo Ochoa (grant CEX2020-001041-S funded by MICIN/AEI/https://doi.org/10.13039/ 501100011033).es_ES
dc.language.isoenges_ES
dc.publisherSpringer es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshHeart Failure es_ES
dc.subject.meshAortic Valve Stenosis es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMice es_ES
dc.subject.meshAnimals es_ES
dc.subject.meshReceptors, Adrenergic, beta-3es_ES
dc.subject.meshMitochondrial Dynamics es_ES
dc.subject.meshHypertrophy, Left Ventricular es_ES
dc.subject.meshMyocytes, Cardiaces_ES
dc.subject.meshMice, Transgenic es_ES
dc.subject.meshMetalloendopeptidases es_ES
dc.titleBeta-3 adrenergic receptor overexpression reverses aortic stenosis-induced heart failure and restores balanced mitochondrial dynamics.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID36445563es_ES
dc.format.volume117es_ES
dc.format.number1es_ES
dc.format.page62es_ES
dc.identifier.doi10.1007/s00395-022-00966-zes_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) es_ES
dc.contributor.funderUnión Europea. Comisión Europea es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderUnión Europea. Comisión Europea. European Research Council (ERC) es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.contributor.funderFundación BBVA es_ES
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERCV (Enfermedades Cardiovasculares) es_ES
dc.contributor.funderComunidad de Madrid (España) es_ES
dc.contributor.funderEuropean Science Foundationes_ES
dc.contributor.funderFundación ProCNIC es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1435-1803es_ES
dc.relation.publisherversion10.1007/s00395-022-00966-zes_ES
dc.identifier.journalBasic research in cardiologyes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovasculares_ES
dc.repisalud.institucionCNICes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/AC16/00021es_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RETOS2019-107332RB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/ERC-CoG/819775es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2019-104776RB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/CB16/11/00399es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD16/0011/0021es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/BBVA/BIO14_298es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/2017-T1/BMD-5185es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RYC2020- 028884-Ies_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/BES-2012–061091es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PFIS FI17/00045es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/FPU2017/01932es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/S2017/BMD-3867es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/P2022/ BMD-7403es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/CEX2020-001041-Ses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional